Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001193125-26-013015·Aktis Oncology, Inc.
Schedule 13D ownership disclosure
Aktis Oncology, Inc.
Common Stock, $0.0001 par value per share · CUSIP: 01021M104
Event date: 2026-01-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Vida Ventures II, LLCReported CIK 0001776851
Shares: 5,671,825 · Class: 10.6%
- Vida Ventures II-A, LLCReported CIK 0001781930
Shares: 157,387 · Class: 0.3%
- VV Manager II LLCReported CIK 0001824569
Shares: 5,829,212 · Class: 10.9%
- Helen KimReported CIK 0001422772
Shares: 5,831,315 · Class: 10.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-013015
- Form type
- SCHEDULE 13D
- Filer
- Aktis Oncology, Inc.
- CIK
- CIK 2035832
- Filed
- Jan 14, 2026
- Reporting period
- Jan 12, 2026
- Description
- Schedule 13D beneficial ownership